Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.

Gillison ML, Akagi K, Xiao W, Jiang B, Pickard RKL, Li J, Swanson BJ, Agrawal AD, Zucker M, Stache-Crain B, Emde AK, Geiger HM, Robine N, Coombes KR, Symer DE.

Genome Res. 2019 Jan;29(1):1-17. doi: 10.1101/gr.241141.118. Epub 2018 Dec 18.

PMID:
30563911
2.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT.

Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.

PMID:
30449625
3.

In Regard to Bossi et al.

Fakhry C, Nguyen-Tân PF, Lambert L, Rosenthal DI, Weber RS, Gillison ML, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):669-670. doi: 10.1016/j.ijrobp.2018.06.020. No abstract available.

PMID:
30238902
4.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

PMID:
29884413
5.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

PMID:
29866947
6.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
7.

Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer.

Jensen GL, Blanchard P, Gunn GB, Garden AS, David Fuller C, Sturgis EM, Gillison ML, Phan J, Morrison WH, Rosenthal DI, Frank SJ.

Clin Transl Radiat Oncol. 2017 Nov 6;7:28-35. doi: 10.1016/j.ctro.2017.09.008. eCollection 2017 Dec.

8.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
9.

HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression.

Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, Symer DE, Aladjem MI, McBride AA.

PLoS Genet. 2018 Jan 24;14(1):e1007179. doi: 10.1371/journal.pgen.1007179. eCollection 2018 Jan.

10.

Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer.

Börnigen D, Ren B, Pickard R, Li J, Ozer E, Hartmann EM, Xiao W, Tickle T, Rider J, Gevers D, Franzosa EA, Davey ME, Gillison ML, Huttenhower C.

Sci Rep. 2017 Dec 15;7(1):17686. doi: 10.1038/s41598-017-17795-z.

11.

Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.

Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, Gillison ML.

J Clin Oncol. 2018 Jan 20;36(3):262-267. doi: 10.1200/JCO.2017.75.0141. Epub 2017 Nov 28.

12.

THE AUTHORS REPLY.

Wyss AB, Hashibe M, Lee YA, Chuang SC, Muscat J, Chen C, Schwartz SM, Smith E, Zhang ZF, Morgenstern H, Wei Q, Li G, Kelsey KT, Winn DM, Gillison ML, Zevallos JP, Boffetta P, Olshan AF.

Am J Epidemiol. 2017 Sep 1;186(5):625-626. doi: 10.1093/aje/kwx212. No abstract available.

13.

Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.

Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML.

J Clin Oncol. 2017 Dec 20;35(36):4057-4065. doi: 10.1200/JCO.2016.72.0748. Epub 2017 Aug 4.

14.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

PMID:
28651929
15.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
16.

Sinonasal adenoid cystic carcinoma: Treatment outcomes and association with human papillomavirus.

Miller ED, Blakaj DM, Swanson BJ, Xiao W, Gillison ML, Wei L, Bhatt AD, Diavolitsis VM, Wobb JL, Kang SY, Carrau RL, Grecula JC.

Head Neck. 2017 Jul;39(7):1405-1411. doi: 10.1002/hed.24778. Epub 2017 Apr 3.

17.

Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer.

Taberna M, Inglehart RC, Pickard RK, Fakhry C, Agrawal A, Katz ML, Gillison ML.

Cancer. 2017 Apr 1;123(7):1156-1165. doi: 10.1002/cncr.30564. Epub 2017 Feb 14.

18.

Nivolumab for Squamous-Cell Cancer of Head and Neck.

Ferris R, Gillison ML.

N Engl J Med. 2017 Feb 9;376(6):596. doi: 10.1056/NEJMc1615565. No abstract available.

PMID:
28177863
19.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

20.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

21.

The association of medication use with clearance or persistence of oral HPV infection.

Lam JO, Sugar EA, Cranston RD, Weber KM, Burk RD, Wiley DJ, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Coles CL, Bream JH, Rositch AF, Guo Y, Xiao W, Gillison ML, D'Souza G.

Cancer Causes Control. 2016 Dec;27(12):1491-1498. Epub 2016 Nov 1.

22.

Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium.

Wyss AB, Hashibe M, Lee YA, Chuang SC, Muscat J, Chen C, Schwartz SM, Smith E, Zhang ZF, Morgenstern H, Wei Q, Li G, Kelsey KT, McClean M, Winn DM, Schantz S, Yu GP, Gillison ML, Zevallos JP, Boffetta P, Olshan AF.

Am J Epidemiol. 2016 Nov 15;184(10):703-716. doi: 10.1093/aje/kww075.

23.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

24.

Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.

Chaturvedi AK, D'Souza G, Gillison ML, Katki HA.

Oral Oncol. 2016 Sep;60:61-7. doi: 10.1016/j.oraloncology.2016.06.006. Epub 2016 Jul 8.

PMID:
27531874
25.

Human Papillomavirus and Oropharyngeal Cancer Stage.

Gillison ML.

J Clin Oncol. 2016 Jun 1;34(16):1833-5. doi: 10.1200/JCO.2016.66.6081. Epub 2016 Apr 25. No abstract available.

PMID:
27114590
26.

Association of serum cytokines with oral HPV clearance.

Lam JO, Bream JH, Sugar EA, Coles CL, Weber KM, Burk RD, Wiley DJ, Cranston RD, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Guo Y, Xiao W, Gillison ML, D'Souza G.

Cytokine. 2016 Jul;83:85-91. doi: 10.1016/j.cyto.2016.04.002. Epub 2016 Apr 8.

27.

Sex Differences in Risk Factors and Natural History of Oral Human Papillomavirus Infection.

D'Souza G, Wentz A, Kluz N, Zhang Y, Sugar E, Youngfellow RM, Guo Y, Xiao W, Gillison ML.

J Infect Dis. 2016 Jun 15;213(12):1893-6. doi: 10.1093/infdis/jiw063. Epub 2016 Feb 10.

PMID:
26908748
28.

The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk.

Rollison DE, Gillison ML.

JAMA Oncol. 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5686. [Epub ahead of print] No abstract available.

PMID:
26797496
29.

Elective versus Therapeutic Neck Dissection in Oral Cancer.

Fakhry C, Yom S, Gillison ML.

N Engl J Med. 2015 Dec 17;373(25):2476. doi: 10.1056/NEJMc1511351. No abstract available.

PMID:
26672855
30.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N.

BMC Infect Dis. 2015 Nov 25;15:544. doi: 10.1186/s12879-015-1281-5.

31.

Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling.

Romick-Rosendale LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, Brusadelli MG, Potter SS, Komurov K, Brugmann SA, Lambert PF, Kimple RJ, Virts EL, Hanenberg H, Gillison ML, Wells SI.

Clin Cancer Res. 2016 Apr 15;22(8):2062-73. doi: 10.1158/1078-0432.CCR-15-2209. Epub 2015 Nov 24.

32.

Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder.

Yom SS, Gillison ML, Trotti AM.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):986-8. doi: 10.1016/j.ijrobp.2015.09.002. Epub 2015 Nov 11. No abstract available.

PMID:
26581136
33.

Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient.

Gillison ML, Restighini C.

Hematol Oncol Clin North Am. 2015 Dec;29(6):1045-60. doi: 10.1016/j.hoc.2015.08.003. Epub 2015 Oct 17. Review.

PMID:
26568547
34.

Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C.

J Clin Oncol. 2015 Oct 10;33(29):3235-42. doi: 10.1200/JCO.2015.61.6995. Epub 2015 Sep 8. Review.

35.

Oropharyngeal cancer survivorship in Denmark, 1977-2012.

Fakhry C, Andersen KK, Eisele DW, Gillison ML.

Oral Oncol. 2015 Nov;51(11):982-984. doi: 10.1016/j.oraloncology.2015.08.006. Epub 2015 Aug 28.

PMID:
26319353
36.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G.

JAMA Oncol. 2015 Oct;1(7):907-15. doi: 10.1001/jamaoncol.2015.2524.

PMID:
26226294
37.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

38.

Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.

Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M.

Oral Oncol. 2015 Aug;51(8):751-8. doi: 10.1016/j.oraloncology.2015.05.007. Epub 2015 Jun 18.

39.

High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV Infection.

Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G.

J Infect Dis. 2015 Nov 15;212(10):1588-91. doi: 10.1093/infdis/jiv273. Epub 2015 May 7.

40.

NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men.

Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Gillison ML.

Cancer Res. 2015 Jun 15;75(12):2468-77. doi: 10.1158/0008-5472.CAN-14-2843. Epub 2015 Apr 14.

41.

Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.

Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML.

Sex Transm Dis. 2015 May;42(5):246-52. doi: 10.1097/OLQ.0000000000000264.

42.

A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.

Beachler DC, Viscidi R, Sugar EA, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Reddy S, Gillison ML, D'Souza G.

Sex Transm Dis. 2015 Feb;42(2):93-7. doi: 10.1097/OLQ.0000000000000236.

43.

Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML.

J Clin Oncol. 2015 Jan 10;33(2):156-64. doi: 10.1200/JCO.2014.56.5218. Epub 2014 Dec 8.

44.

Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, Cranston RD, Burk RD, Minkoff H, Reddy S, Xiao W, Guo Y, Gillison ML, D'Souza G.

Am J Epidemiol. 2015 Jan 1;181(1):40-53. doi: 10.1093/aje/kwu247. Epub 2014 Dec 4.

45.

Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT.

J Clin Oncol. 2014 Dec 1;32(34):3858-66. doi: 10.1200/JCO.2014.55.3925. Epub 2014 Nov 3.

46.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

47.

Tobacco use and oral HPV-16 infection.

Fakhry C, Gillison ML, D'Souza G.

JAMA. 2014 Oct 8;312(14):1465-7. doi: 10.1001/jama.2014.13183. No abstract available.

48.

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT.

J Clin Oncol. 2014 Dec 10;32(35):3930-8. doi: 10.1200/JCO.2013.54.5228. Epub 2014 Sep 29.

49.

Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults.

D'Souza G, Kluz N, Wentz A, Youngfellow RM, Griffioen A, Stammer E, Guo Y, Xiao W, Gillison ML.

Cancers (Basel). 2014 Aug 14;6(3):1691-704. doi: 10.3390/cancers6031691.

50.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS.

J Clin Oncol. 2014 Sep 20;32(27):2940-50.

Supplemental Content

Loading ...
Support Center